AstraZeneca to discover and develop siRNA therapeutics for Cardiovascular, Renal, Metabolic and Respiratory diseases in new collaboration
Collaboration with Silence Therapeutics aims to develop novel, targeted treatments to address significant unmet needAstraZeneca will collaborate with Silence Therapeutics to discover, develop and commercialise small interfering RNA (siRNA) therapeutics for the treatment of Cardiovascular, Renal, Metabolic and Respiratory diseases. This multi-target collaboration will harness Silence’s established siRNA platform to identify and progress liver-based targets, as well as developing new delivery approaches for targeting other tissues such as the heart, lung and kidney. Targeted delivery